Jinghui Lin - Publications

Self-assembled silk fibroin as an interfacial reinforcer: A synergistic strategy with amorphous calcium phosphate for durable dentin bonding.

Journal: Materials today. Bio

Published: September 21, 2025

Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-naïve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial.

Journal: Frontiers in immunology

Published: September 16, 2025

Efficacy and safety of metronomic oral vinorelbine and its combination therapy as second- and later-line regimens for advanced non-small-cell lung cancer: a retrospective analysis.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 22, 2024

Long-term trends of lung cancer incidence and survival in southeastern China, 2011-2020: a population-based study.

Journal: BMC pulmonary medicine

Published: November 06, 2023

Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure.

Journal: Oncology letters

Published: October 23, 2023

Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutant Advanced NSCLC Beyond Limited Progression on Osimertinib.

Journal: Anti-cancer agents in medicinal chemistry

Published: January 17, 2023

Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial.

Journal: Journal of inflammation research

Published: March 27, 2021

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling.

Journal: OncoTargets and therapy

Published: April 19, 2020

Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line.

Journal: Translational cancer research

Published: November 14, 2019

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.

Journal: Scientific reports

Published: December 09, 2016